Dopamine menus: Give your brain some space
'A dopamine menu is a rebranding of what psychologists or healthcare professionals previously called behavioral activation - ways to get yourself to do what's best for you, instead of what you feel like doing in the moment,' Dr. Wilfahrt says.
In this case, the best route to getting that tough task done is to step away from it for a minute, do something else that feeds you energy and then dive back into the task.
The purpose? To stimulate dopamine- a hormone and neurotransmitter in the brain involved in mood, attention, reward and motivation. It's also known as the 'feel-good hormone.' Dopamine comes in many forms - reaching for your phone to doomscroll social media is an easy and convenient way to get a bit of a lift, but that's not the only option. What other accessible activities can bring you joy and a happy brain break?
Examples of healthy 'dopamenu' activities include:
--Going for a brief walk.
--Jamming out to your favorite song.
--Making a cup of tea.
--Petting your dog or cat.
--Lighting a candle.
--Reaching out to a friend or family member.
'The idea is to break up what you're doing,' says Dr. Wilfahrt. And if the selected menu item is purposeful, you can feel a sense of reward for small progresses.
When are dopamine menus most useful? If we're not necessarily enthusiastic about the task we've been assigned, we struggle to maintain attention or interest. We then risk not meeting the expectation or obligation. We feel bad about it, get flooded with remorse and have an even tougher time completing the task due to that sense of anxiety.
'It can become a vicious cycle,' says Dr. Wilfahrt. 'It can be easy to become avoidant when we're in these sort of doom loops.'
So how can you stop this cycle? Brainstorm. Make a mental or physical list of things you can do to get recentered.
Dr. Wilfahrt says the more recently rebranded concept tends to be targeted to people with ADHD, but anyone would benefit:
'It's not a bad idea for anybody to know how to best manage energy. Sitting still to labor over one idea isn't healthy for anyone.'
And while activities on your dopamine menu are meant to be enjoyable, don't forget to go back to the hard task. A journey to the dopamine menu is meant to provide a burst of enthusiasm, not to be something that sucks you in. Consider setting a timer - perhaps for an unusual interval like 13 minutes and 17 seconds. Enjoy the boost and get back to the (real) to-do list.
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
13 hours ago
- Time Business News
Lexapro vs Zoloft: Who Should Avoid Each One?
When it comes to treating depression and anxiety, zoloft vs lexapro are two of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). While both medications are effective for many people, they are not suitable for everyone. Understanding who should avoid Lexapro or Zoloft can help patients and healthcare providers make more informed decisions about mental health treatment. In this blog, we'll explore the key differences between Lexapro and Zoloft and highlight the groups of people who should exercise caution or avoid these medications entirely. Choosing the right treatment for adults dealing with both ADHD and anxiety can be complex. Stimulants like Vyvanse or non-stimulants such as Strattera may be effective, but individual needs vary. For those sensitive to stimulants, non-stimulants often offer better tolerance. It's crucial to find the best ADHD medication for adults with anxiety that manages focus without worsening anxious symptoms. Consulting a psychiatrist is essential to tailor a plan that balances both conditions. Often, therapy combined with medication offers the most comprehensive relief, helping individuals regain control over daily tasks and emotional well-being. Lexapro (escitalopram) and Zoloft (sertraline) are antidepressants that belong to the SSRI class. They work by increasing the levels of serotonin in the brain, a neurotransmitter that plays a critical role in mood regulation. Lexapro is commonly prescribed for major depressive disorder (MDD) and generalized anxiety disorder (GAD), while Zoloft is approved for a broader range of conditions, including depression, anxiety disorders, panic disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). While Lexapro is generally well-tolerated, certain individuals should avoid it or only use it under close medical supervision. These include: Lexapro can trigger manic episodes in individuals with bipolar disorder. If taken without a mood stabilizer, SSRIs like Lexapro may cause a sudden shift from depression to mania. This risk makes it essential for anyone with a history of bipolar disorder or undiagnosed mood swings to undergo thorough psychiatric evaluation before starting Lexapro. Lexapro should never be taken in combination with MAOIs or within 14 days of stopping one. Combining these medications can lead to a potentially life-threatening condition known as serotonin syndrome. This condition causes symptoms like agitation, hallucinations, rapid heart rate, and high blood pressure. Since Lexapro is metabolized in the liver, individuals with significant liver impairment may be at increased risk of drug accumulation and toxicity. Dosage adjustments or alternative medications may be necessary in such cases. Although Lexapro may be prescribed during pregnancy if the benefits outweigh the risks, it's not typically the first choice. Some studies have shown potential risks of birth defects and neonatal complications. Breastfeeding women should also use Lexapro with caution, as small amounts of the drug can pass into breast milk. Lexapro is approved for use in adolescents aged 12 and older for the treatment of depression. However, younger children should not take Lexapro unless specifically directed by a specialist. The drug may increase the risk of suicidal thoughts in young users, particularly during the first few weeks of treatment. Zoloft has a broader range of approved uses than Lexapro, but it also comes with specific risks. The following individuals should avoid Zoloft or consult their healthcare provider before taking it: Zoloft can lower the seizure threshold and may increase the risk of seizures in individuals with epilepsy or other seizure conditions. Such patients need close monitoring or an alternative medication. Anyone who has previously experienced serotonin syndrome should avoid Zoloft, as it can trigger a recurrence. Combining Zoloft with other serotonergic drugs also increases this risk and should be avoided unless absolutely necessary. Zoloft can increase the risk of bleeding, especially when taken with medications like aspirin, warfarin, or nonsteroidal anti-inflammatory drugs (NSAIDs). This risk is particularly high in older adults or individuals with a history of gastrointestinal bleeding. Alcohol can amplify the sedative effects of Zoloft and increase the risk of liver toxicity and mood instability. Patients with a history of alcohol abuse or dependence should be cautious and may need a different treatment plan. Zoloft may increase intraocular pressure, potentially worsening narrow-angle glaucoma. Patients with this eye condition should alert their ophthalmologist and psychiatrist before starting Zoloft. While both drugs treat similar conditions, Lexapro is often noted for having a slightly better side effect profile and fewer drug interactions. However, Zoloft is more versatile in treating multiple anxiety-related disorders. When choosing between them, doctors consider the patient's medical history, existing conditions, other medications, and specific symptoms. Lexapro and Zoloft are powerful tools in managing depression and anxiety, but they are not one-size-fits-all solutions. Lexapro may not be ideal for those with liver issues, bipolar disorder, or who are pregnant or breastfeeding. On the other hand, Zoloft may be risky for individuals with seizure disorders, bleeding risks, or glaucoma. Always consult a qualified healthcare provider before starting or stopping any antidepressant. Personalized care is essential in finding the safest and most effective treatment for your mental health needs. TIME BUSINESS NEWS
USA Today
14 hours ago
- USA Today
Lizzo reveals meal plan that helped her achieve weight loss goal
After announcing she has achieved her "weight release goal," Lizzo is now dropping the routine that helped her get there. Lizzo, whose real name is Melissa Viviane Jefferson, 37, in a cover story for Women's Health's latest issue, opened up about her physical health journey and revealed the routine she followed to "release" 16% of her body fat. Need a break? Play the USA TODAY Daily Crossword Puzzle. Lizzo's meal plans To achieve her goal, Lizzo detailed in the interview published online July 1 that her meals consist mainly of protein and vegetables. For breakfast, her go-to option is two scrambled eggs, chicken sausage and a cauliflower hash brown. For lunch, the Grammy-winning artist switches between shredded Thai chicken salad, lettuce wraps stuffed with tuna and sliced chicken breast. As for dinner, which she eats at 5 p.m., Lizzo prefers to stick with the same one: a turkey meatloaf with cauliflower mashed potatoes and green beans. "I have GERD (gastroesophageal reflux disease), so my body needs time to digest food before I go to sleep, so acid doesn't roll up to my throat," Lizzo explained about her early dinner. GERD, according to Mayo Clinic, is "when stomach acid flows back up into the esophagus and causes heartburn." Other symptoms include backwash of food or sour liquid in the throat, upper belly or chest pain and trouble swallowing. A snack for Lizzo typically is low-sugar Greek yogurt with blueberries or blackberries and a little honey on top and she's traded multiple Frappuccinos a day for one cup of coffee with vanilla protein. TikTok has banned #SkinnyTok: Will it make a difference? True health is in balance However, at the same time, Lizzo says she does give into her cravings, occasionally indulging in a waffle with chicken tenders, crab legs, or a coconut cream–filled doughnut. 'There's a balance,' she says of her food choices. 'I think that's what true health is.' Lizzo, in January 2025, had announced she had achieved her "weight release goal," revealing she had lowered her body mass index (BMI) by 10.5 and lost 16% of her body fat since January 2023. The artist, in the interview, shared her journey toward health started after she was hit with a series of sexual harassment and weight shaming allegations, which she referred to as 'a shocking, really hurtful accusation,' during the summer of 2023. Lizzo has maintained innocence, and the case is ongoing in Los Angeles Superior Court. In December 2024, her name was dropped from a harassment lawsuit, USA TODAY previously reported. Did Lizzo take Ozempic to lose weight? Lizzo told the magazine she did not take weight loss drug Ozempic during her journey, though she contemplated weight loss surgery and cosmetic procedures like a tummy tuck. While she chose not to go that route, she doesn't condemn it. The rapper had earlier also slammed allegations that she was taking Ozempic. Saman Shafiq is a trending news reporter for USA TODAY. Reach her at sshafiq@ and follow her on X and Instagram @saman_shafiq7.
Miami Herald
16 hours ago
- Miami Herald
Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
ROCHESTER, Minn. - Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan - a transformative advance in early, accurate diagnosis. The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. The rising toll of dementia Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program. 'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' Dr. Jones says. 'That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment - a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases.' To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer. 'As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,' Dr. Barnard says. 'Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.' Turning brain patterns into clinical insight The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
